Search
dihydrotachysterol; DHT, (Hytakerol, Dichystrolum, Antitanil)
Tradename: Hytakerol
Indications:
- acute or chronic post-operative tetany (especially thyroid surgery)
- idiopathic tetany
- hypoparathyroidism
- hypophosphatemia
- hypocalcemia
- renal osteodystrophy
- rickets
Dosage:
1) 0.8-2.4 mg QD for several days
2) maintenance dose is 0.2-1.0 mg QD
Tabs: 0.125, 0.2, 0.4 mg.
Pharmacokinetics:
1) readily absorbed from intestine
2) absorption may be reduced by hepatobiliary disease or steatorrhea
3) maximal hypercalcemic effects occur in about 4 weeks after daily administration of a fixed dose
4) 1/2life is 3-6 hours
Adverse effects:
1) common (> 10%)
- hypercalcemia, hypercalciuria, elevated serum creatinine
2) uncommon (< 1%)
- nausea/vomiting, anorexia, convulsions, weakness, anemia, metastatic calcification, renal injury
3) other [1]
- headache
- somnolence
- dry mouth
- constipation
- late adverse effects (uncommon (< 1%))
- polyuria
- polydipsia
- irritability
- weight loss
Drug interactions:
1) concurrent use of antacids may lead to hypermagnesemia in patients with renal failure
2) cholestyramine, colestipol & mineral oil decrease serum vitamin D levels
3) phenytoin & phenobarbital decrease serum vitamin D levels
Mechanism of action:
1) vitamin D hydroxylated by hepatic microsomal enzymes to form cacifediol (25-OH vit D)
2) calcifediol is hydroxylated in the kidneys to calcitriol (1,25 dihydroxy-vit D)
3) calcitriol is the most active form of vitamin D, simulating intestinal transport of calcium & phosphorous
Interactions
drug interactions
General
vitamin D
Properties
MISC-INFO: elimination route LIVER
1/2life 3-6 HOURS
pregnancy-category C
safety in lactation ?
Database Correlations
PUBCHEM correlations
References
- Drug Information & Medication Formulary, Veterans Affairs,
Central California Health Care System, 1st ed., Ravnan et al
eds, 1998
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Deprecated Reference